scholarly journals Four-week Urticaria Activity Score-7 as a Useful Patient-reported Outcome to Assess Chronic Spontaneous Urticaria: A Multicentre Study Evaluation of Adherence and Patients’ Perspective

2019 ◽  
Vol 99 (10) ◽  
pp. 903-904 ◽  
Author(s):  
C Patruno ◽  
M Napolitano ◽  
S Ferrucci ◽  
L Brambilla ◽  
K Hansel ◽  
...  
Keyword(s):  
Multicentre Study ◽  
Patient Reported Outcome ◽  
Chronic Spontaneous Urticaria ◽  
Activity Score ◽  
Study Evaluation ◽  
Patient Reported ◽  
Urticaria Activity Score ◽  
Patients Perspective

scholarly journals N07 Patient reported outcome measures collected from patients using a digital tablet: early benefits

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S660-S661
Author(s):  
P Avery ◽  
K Blackmore ◽  
C Angel
Keyword(s):  
Disease Activity ◽  
Outcome Measures ◽  
Disease Activity Score ◽  
Patient Reported Outcome Measures ◽  
Patient Reported Outcome ◽  
Activity Score ◽  
Data Set ◽  
Patient Reported ◽  
The Impact ◽  
Digital Tablet

Abstract Background At a district general hospital (DGH) on the south coast of England the inflammatory bowel disease (IBD) nurse led service introduced an eHealth system in 2015 linked to the IBD registry but limited to access via a desktop limiting flexibility. In liaison with the IBD registry and the software developer the lead nurse instigated an upgrade to the system. This allows patients access both remotely and via a digital tablet in outpatients. Discussion is being had about the best way to collect patient reported outcome measures (PROMS) both for large data analyse and local patient benefit. This presentation of the first 3 months collection of the PROMS seeks to show the benefit of these data locally Methods PROMS were gathered from both Consultant and Nurse led clinics from July 2019 to the 22 October 2019. Patients were asked to fill in the IBD control PROM (this PROM forms part of the IBD registry Data set) on a tablet before entering the consultation room. Additionally a disease activity score either the Harvey Bradshaw Score (HBI) or the Simple Clinical Colitis activity index (SCCAI) is collected at the same time. These scores were then extracted from the system and evaluated using a descriptive data analysis approach. Results After Data cleansing 200 records are shown in Table 1 covering all disease sub-types. Fatigue was the most commonly reported complication of IBD in addition,126 patients who attended outpatients reported a wellness score of above 75 out of 100 isolating the wellness score from the PROM score allowed a comparison with the corresponding disease activity score in these patients and correlated in 95% of UC Patients and CD 84% (see Table 2). Conclusion Fatigue is a widely reported symptom of IBD as well as pain and anxiety or depression. These data confirm this trend but also present the first local population information for the IBD service at this DGH. When looking at the impact of these scores there is an opportunity to identify patients that may need medically optimising. The patients that remain could then be targeted with support services and a business case for counselling is now planned. In addition to this together with self-testing with IBDoc ® the PROMs and disease activity scores provide opportunity for remote management of some patients. These PROMs collected from patients using a tablet in outpatients at a DGH show promising value for service development.

scholarly journals P11.01 Patient-reported outcome measures in meningioma research - lack of the patients perspective

2016 ◽  
Vol 18 (suppl_4) ◽  
pp. iv65-iv65
Author(s):  
A. H. Zamanipoor Najafabadi ◽  
L. Dirven ◽  
M. L. D. Broekman ◽  
W. C. Peul ◽  
M. J. B. Taphoorn ◽  
...  
Keyword(s):  
Outcome Measures ◽  
Patient Reported Outcome Measures ◽  
Patient Reported Outcome ◽  
Patient Reported ◽  
Patients Perspective

scholarly journals Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome

2017 ◽  
Vol 13 (1) ◽  
Author(s):  
Hermenio Lima ◽  
Melinda Gooderham ◽  
Jan Dutz ◽  
Charles Lynde ◽  
Hugo Chapdelaine ◽  
...  
Keyword(s):  
Patient Reported Outcome ◽  
Chronic Spontaneous Urticaria ◽  
Treat To Target ◽  
Patient Reported

Chronisch-spontane Urtikaria: Viel hilft manchmal eben doch viel

2019 ◽  
pp. 193-194
Author(s):  
Wiebke Sondermann
Keyword(s):  
Retrospective Analysis ◽  
Baseline Data ◽  
Chronic Spontaneous Urticaria ◽  
Recommended Dose ◽  
Activity Score ◽  
Control Test ◽  
Stepwise Approach ◽  
Patient Will ◽  
Urticaria Activity Score ◽  
Higher Doses

The recommended dose of omalizumab for the treatment of chronic spontaneous urticaria (CSU) is 300 mg every 4 weeks, but there is no recommendation for patients who do not benefit from this dose. Our aim is to present the experiences on the use of doses of omalizumab higher than those recommended for CSU patients and to propose a protocol for updosing. This was a retrospective analysis of patients treated with omalizumab for CSU from 2 urticaria centers in Istanbul and Barcelona. The weekly urticaria activity score and/or the Urticaria Control Test (UCT) were used to monitor response. In Barcelona, a stepwise updosing regimen was preferred (450 mg first, then increasing to 600 mg), while in Istanbul, direct updosing to 600 mg was chosen. In Istanbul, 81 (88%) patients were treated with 300 mg, while 11 (12%) received 600 mg of omalizumab. In Barcelona, 7 (8.8%), 45 (56.3%), 17 (21.3%), and 11 (13.8%) patients received 150, 300, 450, and 600 mg of omalizumab, respectively. Urticaria control was achieved in 82.6% of the patients with 300 mg and in 8.7% of the patients with 600 mg in Istanbul, while it was achieved with 150 mg in 10%, with 300 mg in 48.8%, with 450 mg in 16.3%, and with 600 mg in 6.3% of the patients in Barcelona. In total, 123 (71.5%) patients responded to 150-300 mg and 26 (15.1%) to 450-600 mg. When responders to 150-300 mg (n = 123) were compared with responders to 450-600 mg (n = 26), BMI was found to be higher, and pre-omalizumab UCT was found to be lower in patients receiving updosed omalizumab (p = 0.029). Baseline data of the patients, especially BMI and pre-oma UCT, might be useful to determine if the patient will require higher doses of omalizumab. We recommend a stepwise approach starting from 450 mg and then updosing to 600 mg in CSU patients who do not respond or partially respond to 300 mg of omalizumab after 3-6 months of treatment.

Thermoablation of thyroid nodules reveals excellent results with low morbidity

2021 ◽  
pp. 1-7
Author(s):  
Robert M. Eisele ◽  
Philipp R. Scherber ◽  
Monika Schlüter ◽  
Thorsten Drews ◽  
Matthias Glanemann ◽  
...  
Keyword(s):  
Preoperative Diagnosis ◽  
Thyroid Nodules ◽  
Patient Reported Outcome ◽  
European Federation ◽  
Minimal Invasiveness ◽  
Patient Reported ◽  
Microwave System ◽  
Patients Perspective ◽  
Autonomous Adenoma

BACKGROUND: Thermoablation is an attractive treatment of thyroid nodules for its minimal-invasiveness. It remains unclear whether results and morbidity meet the patients’ expectations. OBJECTIVE: The aim of the presented study is to show data obtained after microwave thyroid ablation from a patients’ perspective. METHODS: Indications and preoperative diagnosis were chosen according to international guidelines. Thermoablation was achieved using a CE certified microwave system. The procedures heeded the published recommendations of the European Federation of Societies for Ultrasound in Medicine and Biology. Follow-up included ultrasound, laboratory parameters and a standardized questionnaire. RESULTS: Thirty patients were enrolled into the study. All patients reported an improvement of complaints following the procedure. Scar formation occurred in 3 cases (10%) with 0.5 ± 1.3 mm length and 0.4 ± 1.0 mm width. No cosmetic, neurological, vocal or pharyngeal complication occurred. Energy required for non-functioning nodules (n= 15, 50%) was 2.56 ± 3.41 kJ/mL, for autonomous adenoma (n= 8, 27%) 0.96 kJ/mL (p< 0.05, t-test). CONCLUSION: The presented data summarize an initial experience in selected patients and resemble excellent patient reported outcome with minimal morbidity. These preliminary data indicate the majority of patients satisfied with the procedure. Further trials will be required to endorse these findings.

Sign in / Sign up

Export Citation Format

Share Document